The committee finds that major progress has been made in reducing mortality for women from breast cancer, cardiovascular disease, and cervical cancer. This can be attributed in part to increased consumer demand and awareness, which has resulted in additional funding and research; improved diagnosis; screening and treatment; and, in the case of cervical cancer, a vaccine.
More limited advances have been made in depression, HIV/AIDS, and osteoporosis, the committee finds. Few advances have been made in reducing unintended pregnancy, autoimmune diseases, maternal morbidity and mortality, alcohol and drug addiction, lung cancer, gynecological cancers other than cervical cancer, non-malignant gynecological disorders, and Alzheimer’s disease.
The committee has observed that there have been fewer advances in research investigating non-fatal diseases that result in major morbidity for women, despite the high value women place on quality of life as well as longevity. Therefore, the committee recommends that research include greater attention to assessing quality of life — for example, functional status or functionality, mobility, or pain — and promoting wellness. As part of this effort, research should include the development of better measures to compare effects of health conditions, interventions, and treatments on quality of life for women.
Is Women’s Health Research Studying the Most Relevant Groups of Women?
While investments in women’s health research have led to decreased rates of female mortality from some diseases, that progress has not been enjoyed equally by women from all population groups in the US. Large disparities in disease burden remain among groups of women. Women who are socially disadvantaged because of their race or ethnicity, income level, or educational attainment have been underrepresented in many studies and have not benefited as much from the progress in women’s health research.
The IOM committee recommends that NIH, the Agency for Healthcare Research and Quality, and the Centers for Disease Control and Prevention develop targeted initiatives to increase research on the populations of women with the highest risks and burdens of disease.
More Articles
- Women Firefighters Face High Exposure to Toxic ‘Forever Chemicals’ Known to Interfere with Immune and Endocrine Functions and Breast Development
- A Most Unique Statement From FDA Commissioner Scott Gottlieb, M.D., On Efforts to Safeguard Women’s Health From Deceptive Health Claims and Significant Risks Related to Devices Marketed for Use in Medical Procedures for “Vaginal Rejuvenation"
- "A Whole New Dimension to Immune Therapy": Getting a More Robust Immune Reaction Against a Tumor
- After 55: Changing to Every Other Year for Mammograms
- Editorial in JAMA Journal Oncology: Rethinking the Standard for Ductal Carcinoma In Situ Treatment
- 5th White House Science Faire; The Theme? Diversity and Inclusion in STEM
- Congressional Bills Introduced: IRS & Trafficking, Ratifying CEDAW; Campus Sexual Violence; Tax Credits
- "Too Much Medicine": Overdiagnosed and Overtreated, A Scientific Panel Recommends Personalized Cancer Strategies
- The Gene Patent Decision Explained by the Supreme Court Blog: In Plain English
- Are Genes Ownable? Challenging Patents on Breast and Ovarian Cancer Genes in the Supreme Court
